TSC2 and tuberous sclerosis: The reduction in these pro‐angiogenic and pro‐tumoral factors could ameliorate the effects of TSC2‐ cells on their microenvironment, thus rapamycin may not only shrink TSC cyst and tumour size but also reduce the microenvironmental support for growth.